A Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine

Status Completed

Clinical Trial Summary

This an open phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunity persistence after single dose of 23-valent pneumococcal polysaccharide vaccine.

Clinical Trial Description

This study is an open phase Ⅳ clinical trial to evaluate the immunity persistence after single dose of 23-valent pneumococcal polysaccharide vaccine.The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd,the control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd..A total of 600 subjects including 450 subjects in the experimental group and 150 subjects in the control group who participated in the second stage of phase Ⅲ clinical trial (PPS)will be enrolled .Based on the age at the time of enrollment in the phase Ⅲ study, there will be 150 participants in each age group (2-17 years old group, 18-60 years old group and ≥61 years old) in the experimental group and 50 participants in each age group in the control group .3.0-3.5ml of venous blood will be collected from all subjects after enrollment. ;

Study Design

Related Conditions & MeSH terms

Pneumococcal Infections

Clinical Trial Details

NCT number	NCT04989465
Study type	Interventional
Source	Sinovac Biotech Co., Ltd
Contact
Status	Completed
Phase	Phase 4
Start date	September 10, 2021
Completion date	September 13, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02201030` - Immunogenicity and Safety Study of NBP606 in Healthy Infants	Phase 3
Completed	`NCT02787863` - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology	Phase 4
Completed	`NCT04031846` - Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)	Phase 3
Recruiting	`NCT05920499` - The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage	N/A
Completed	`NCT01215175` - Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)	Phase 1
Completed	`NCT02892812` - A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults	Phase 1
Completed	`NCT02116998` - Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae	Phase 2
Completed	`NCT01446926` - Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants	Phase 1
Completed	`NCT01193582` - A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria	Phase 4
Completed	`NCT00744263` - Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults	Phase 4
Completed	`NCT00492557` - Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults	Phase 3
Completed	`NCT00195611` - Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media	Phase 4
Completed	`NCT00205803` - Study Evaluating Pneumococcal Vaccine in Healthy Infants	Phase 1/Phase 2
Completed	`NCT00137605` - Early Versus Delayed Pneumococcal Vaccination in HIV	Phase 1/Phase 2
Completed	`NCT02531373` - A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)	Phase 1/Phase 2
Completed	`NCT03615482` - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)	Phase 3
Completed	`NCT03565900` - A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)	Phase 3
Completed	`NCT02547649` - Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)	Phase 2
Completed	`NCT02573181` - Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)	Phase 2
Completed	`NCT05477693` - Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine	Phase 4